Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.

Consistently, our data demonstrated a highly significant decrease in the expression of this direct MYC target in tumors treated with FPPa-OmoMYC relative to vehicle ( p = 5.16 × 10 −7 ) (Fig. 3c ).

also in 132,142 other papers